title: [DTIC--one component of ABVD combination therapy in Hodgkin's disease (author's transl)].
abstract: 11 pretreated patients with advanced Hodgkin's disease were treated according to the ABVD schedule. In 6 cases this treatment had to be prematurely terminated due to considerable side effects or due to progression of the disease. The other 6 cases responded favourably, but the improvement was only of short duration.
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D003606:Dacarbazine / Q000008:administration & dosage / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D008297:Male; D012075:Remission, Spontaneous; D013997:Time Factors; D014226:Triazenes / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D014226:Triazenes; D003606:Dacarbazine
vernacular_title: DTIC--Bestandteil einer Therapiekombination (ABVD) bei Morbus Hodgkin.